· Published by Health Canada · Official notice
This is duplicated text of a letter from GlaxoSmithKline Inc.
Contact the company for a copy of any references, attachments or enclosures.
GlaxoSmithKline Inc
August 15, 2003
Dear Health Care Professional,
SMART) was prematurely stopped by GlaxoSmithKline due to a small but significant increase in asthma-related deaths in patients receiving SEREVENT® (salmeterol xinafoate) versus those on placebo. Subgroup analyses suggest the risk may be greater in African American patients compared to Caucasians.
SEREVENT® (salmeterol xinafoate) is not approved as an asthma monotherapy in Canada.
SEREVENT® (salmeterol xinafoate) is not a substitute for inhaled or oral corticosteroids.
This letter is being sent out following discussions with Health Canada regarding the use of SEREVENT® (salmeterol xinafoate) in asthma. "SEREVENT® (salmeterol xinafoate) is indicated in the maintenance treatment of asthma in patients 4 years of age and older with reversible obstructive airway disease, who are using optimal corticosteroid treatment and experiencing breakthrough symptoms requiring regular use of a short-acting bronchodilator"Footnote 1.
Background
In January, GSK in the US, communicated findings from an interim analysis of a large study investigating the use of SEREVENT® in patients with asthma. This analysis reported an association between SEREVENT® and rare, but potentially serious asthma-related events. Since that time, GlaxoSmithKline has been reviewing the data with the US Food and Drug Administration (FDA) and has subsequently updated the prescribing information for SEREVENT® and ADVAIR® (salmeterol xinafoate / fluticasone propionate); salmeterol being the active component of SEREVENT® and one of the active components of ADVAIR® . The Canadian product monograph will also be updated as a result of the findings from the SMART study.
SMART Safety Study
In July 1996, GSK initiated the SMART, a 28-week safety study comparing SEREVENT® and placebo in the treatment of asthma. The study was initiated following concerns about the safety of the regular use of short and long-acting beta 2-agonists in the management of asthma that arose as a result of post-marketing reports of several asthma deaths associated with the use of SEREVENT® inhalation aerosol received by the US FDA, as well as the results of the SEREVENT® nationwide surveillance studyFootnote 2.
In addition to their prescribed asthma therapy, patients in one arm of the study received 42 mcg of SEREVENT (N=13,174) twice a day through a metered-dose inhaler (MDI), and patients in the other arm received placebo (N=13,179). In contrast to the situation in Canada, in the United States, SEREVENT® is approved as an asthma monotherapy. Therefore, not all patients enrolled in the SEREVENT® treatment arm of the SMART were taking optimal doses of corticosteroids at study entry.
The primary endpoint of SMART was the combined number of respiratory related deaths or respiratory related life-threatening experiences (intubations and mechanical ventilation). Secondary endpoints analyzed specific subsets of the primary endpoint, the combined number of asthma-related events (asthma-related intubations and asthma-related deaths) as well as asthma-related deaths alone. A planned interim analysis was conducted when approximately half of the intended number of patients were enrolled. Although SMART did not reach predetermined stopping criteria, the study was stopped due to findings in African-American patients and difficulties with enrollment.
The analysis of SMART showed no significant difference for the primary endpoint for the total population. However, a higher number of asthma-related deaths or life-threatening experiences (36 vs. 23) and a higher number of asthma-related deaths (13 vs. 4) occurred in the patients treated with SEREVENT® Inhalation Aerosol. No significant increase was observed in respiratory or asthma-related episodes, including deaths, in Caucasian patients. In African-Americans, the study showed a small, though statistically significantly greater number of primary events (20 vs. 7), asthma-related deaths or life-threatening experiences (19 vs. 4), and asthma-related deaths (8 vs. 1) in patients taking SEREVENT® Inhalation Aerosol compared to those taking placebo. However, due to the low rate of primary events in the study, the findings of the planned interim analysis were not conclusive.
In the United States, the prescribing information has been updated to include a boxed warning. In addition, other sections of the US package insert for SEREVENT® and ADVAIR® (Clinical Trials, Warnings, and Information for Patients) have been updated to include the results from SMART and the following additional information:
Important Advice for Managing Your Patients
GSK believes it is important to reiterate and reinforce advice for the management of patients established in the Canadian Asthma Consensus GuidelinesFootnote 3 and prescribing information for SEREVENT® and ADVAIR®:
The information on the SMART study will be incorporated into the Canadian product monograph.
The identification, characterization, and management of drug-related adverse events are dependent on the active participation of health care professionals in adverse drug reaction reporting programs. Health care professionals are asked to report any suspected adverse reactions in patients receiving SEREVENT® (salmeterol xinafoate) or ADVAIR® (salmeterol xinafoate / fluticasone propionate) directly to GlaxoSmithKline:
GlaxoSmithKline Inc.
7333 Mississauga Road N
Mississauga, Ontario
L5N 6L4
Tel: 1-800-387-7374
Your professional commitment in this regard has an important role in protecting the well-being of your patients by contributing to early signal detection and informed drug use.
Any questions from health care professionals may be directed to our Medical Information department via GlaxoSmithKline Customer Service at 1-800-387-7374.
Sincerely,
original signed by
M.D., FRCPC
Vice President, Research & Development and Chief Medical Officer
GlaxoSmithKline Inc.
® SEREVENT and ADVAIR are registered trademarks, used under license by GlaxoSmithKline Inc.
Any suspected adverse incident can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0201C2
OTTAWA, Ontario, K1A 1B9
Tel: (613) 957-0337 or Fax: (613) 957-0335
Toll free for consumers and health professionals:
Tel: 866 234-2345, Fax: 866 678-6789
cadrmp@hc-sc.gc.ca
The AR Reporting Form and the AR Guidelines can be found on the TPD web site or in The Canadian Compendium of Pharmaceuticals and Specialties.
References:
SEREVENT® (salmeterol xinafoate) Official Canadian Product Monograph. GlaxoSmithKline Inc., 7333 Mississauga Road North, Mississauga, Ontario L5N 6L4. Date of Revision: November 21, 2001
Castle W et. al., Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993; 306:1034-7.
Canadian Asthma Consensus Report, 1999. CMAJ 1999; 161 (11 Suppl).